Myelin Oligodendrocyte Glycoprotein Peptide (35-55), mouse, rat acetate
(Synonyms: MOG (35-55) (acetate)) 目录号 : GC64476Myelin Oligodendrocyte Glycoprotein Peptide (35-55), mouse, rat acetate 是中枢神经鞘的一个次要成分。Myelin Oligodendrocyte Glycoprotein Peptide (35-55), mouse, rat acetate 引发复发缓解性神经系统疾病,伴有广泛的斑块样脱髓鞘。还能诱导强效的 T细胞和 B 细胞反应,同时是高度脑源性的。
Sample solution is provided at 25 µL, 10mM.
Quality Control & SDS
- View current batch:
- Purity: >98.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Myelin Oligodendrocyte Glycoprotein Peptide (35-55), mouse, rat acetate is a minor component of CNS myelin. Myelin Oligodendrocyte Glycoprotein Peptide (35-55), mouse, rat produces a relapsing-remitting neurological disease with extensive plaque-like demyelination. Myelin Oligodendrocyte Glycoprotein Peptide (35-55), mouse, rat acetate induces strong T and B cell responses and is highly encephalitogenic[1][2][3].
Myelin Oligodendrocyte Glycoprotein Peptide (35-55), mouse, rat (MOG) is a highly autoantigenic molecule capable of inducing severe demyelinating disease[2].
[1]. Ichikawa M, et al. Analysis of the fine B cell specificity during the chronic/relapsing course of a multiple sclerosis-like disease in Lewis rats injected with the encephalitogenic myelin oligodendrocyte glycoprotein peptide 35-55. J Immunol. 1996 Jul 15;157(2):919-26.
[2]. Slavin A, et al. Induction of a multiple sclerosis-like disease in mice with an immunodominant epitope of myelin oligodendrocyte glycoprotein. Autoimmunity. 1998;28(2):109-20.
[3]. Zhang GX, et al. T cell and antibody responses in remitting-relapsing experimental autoimmune encephalomyelitis in (C57BL/6 x SJL) F1 mice. J Neuroimmunol. 2004 Mar;148(1-2):1-10.
Cas No. | SDF | Download SDF | |
别名 | MOG (35-55) (acetate) | ||
分子式 | C120H181N35O31S | 分子量 | 2642 |
溶解度 | Water : 100 mg/mL (37.85 mM; Need ultrasonic) | 储存条件 | -20°C, away from moisture |
General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。 储备液的保存方式和期限:-80°C 储存时,请在 6 个月内使用,-20°C 储存时,请在 1 个月内使用。 为了提高溶解度,请将管子加热至37℃,然后在超声波浴中震荡一段时间。 |
||
Shipping Condition | 评估样品解决方案:配备蓝冰进行发货。所有其他可用尺寸:配备RT,或根据请求配备蓝冰。 |
制备储备液 | |||
1 mg | 5 mg | 10 mg | |
1 mM | 0.3785 mL | 1.8925 mL | 3.785 mL |
5 mM | 0.0757 mL | 0.3785 mL | 0.757 mL |
10 mM | 0.0379 mL | 0.1893 mL | 0.3785 mL |
第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量) | ||||||||||
给药剂量 | mg/kg | 动物平均体重 | g | 每只动物给药体积 | ul | 动物数量 | 只 | |||
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系GLPBIO为您提供正确的澄清溶液配方) | ||||||||||
% DMSO % % Tween 80 % saline | ||||||||||
计算重置 |
计算结果:
工作液浓度: mg/ml;
DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,
体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL saline,混匀澄清。
1. 首先保证母液是澄清的;
2.
一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。